SI-BONE to Participate at the 31st Annual Piper Jaffray Healthcare Conference on December 5, 2019
04 December 2019 - 8:05AM
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company
dedicated to solving musculoskeletal disorders of the sacropelvic
anatomy, today announced that management will participate in the
upcoming 31st Annual Piper Jaffray Healthcare Conference in New
York.
SI-BONE’s management is scheduled to participate
on Thursday, December 5, 2019 at 11:30 a.m. Eastern Time.
Interested parties may access a live and archived webcast of the
session on the “Investors” section of the company’s website at:
www.si-bone.com.
About SI-BONE
SI-BONE is a medical device company that
pioneered minimally invasive surgery of the SI joint with the iFuse
Implant System. Studies have shown that the SI joint can be a
source of pain in 15% to 30% of chronic low back pain. The
iFuse Implant™, commercially available since 2009, is the only SI
joint fusion device supported by multiple prospective clinical
studies, including two RCTs, showing improved pain, patient
function and quality of life resulting from treatment. There are
over 75 peer-reviewed publications demonstrating the safety,
durable effectiveness, and biomechanical and economic benefits
unique to the iFuse Implant (www.si-bone.com/results). This
body of evidence has enabled multiple government and private
insurance payors to establish coverage of the SI joint fusion
procedure exclusively when performed with the iFuse Implant
System.
The iFuse Implant System is intended for
sacroiliac fusion for conditions including sacroiliac joint
dysfunction that is a direct result of sacroiliac joint disruption
and degenerative sacroiliitis. This includes conditions whose
symptoms began during pregnancy or in the peripartum period and
have persisted postpartum for more than 6 months. The iFuse
Implant System is also intended for sacroiliac fusion to augment
immobilization and stabilization of the sacroiliac joint in
skeletally mature patients undergoing sacropelvic fixation as part
of a lumbar or thoracolumbar fusion.
There are potential risks associated with the
iFuse Implant System. It may not be appropriate for all
patients and all patients may not benefit. Rx Only. For
indications, risks, and safety information visit:
www.si-bone.com/risks.
For more information, visit www.si-bone.com and follow us on
Twitter at @siboneinc.
SI-BONE and iFuse Implant System are registered
trademarks of SI-BONE, Inc. iFuse Implant is a trademark of
SI-BONE, Inc. ©2019 SI-BONE, Inc. All Rights Reserved.
10584.120419
Investor Contacts:Lynn Lewis or Carrie
Mendivilinvestors@SI-BONE.com415-937-5405
SI BONE (NASDAQ:SIBN)
Historical Stock Chart
From Jun 2024 to Jul 2024
SI BONE (NASDAQ:SIBN)
Historical Stock Chart
From Jul 2023 to Jul 2024